PCBL Chemical Q2 FY27 Results: Standalone Net Profit ₹80.01 Crore on Total Income of ₹1,710 Crore
- Earnings
Reviewed byKeshav SehgalBlacklitt Research
PCBL Chemical (NSE: PCBL) reported standalone total income of ₹1,710.10 crore and net profit of ₹80.01 crore for the quarter ended 30 Sep 2026, in a filing on 2 Nov 2026.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹1,710.10 crore, up 15.2% YoY and 3.2% QoQ
- Net profit and EPS: ₹80.01 crore, up 34.2% YoY and down 25.4% QoQ; basic EPS ₹2.03 against ₹1.58 a year earlier
- Finance costs: ₹59.44 crore, down 8.1% YoY and up 21.6% QoQ
- Interim dividend: ₹177.06 crore (₹4.50 a share), declared 29 Jul 2026 and paid in the quarter
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 1,710.10 | 1,484.44 | +15.2% | 1,657.66 | +3.2% | |
| Revenue from operations | 1,694.65 | 1,478.01 | +14.7% | 1,653.48 | +2.5% |
| Other income | 15.45 | 6.43 | +140.3% | 4.18 | +269.6% |
| 80.01 | 59.63 | +34.2% | 107.24 | -25.4% | |
| Profit before tax | 109.51 | 79.83 | +37.2% | 148.29 | -26.2% |
| Finance costs | 59.44 | 64.70 | -8.1% | 48.88 | +21.6% |
| Depreciation | 47.44 | 41.45 | +14.5% | 45.40 | +4.5% |
| Tax expense | 29.50 | 20.20 | +46.0% | 41.05 | -28.1% |
| Net profit margin | 4.68% | 4.02% | +0.66 pp | 6.47% | -1.79 pp |
| EPS, basic (₹) | 2.03 | 1.58 | +28.5% | 2.73 | -25.6% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit rose 34.2% year on year to ₹80.01 crore, faster than total income, which rose 15.2% to ₹1,710.10 crore. Profit before tax rose 37.2% to ₹109.51 crore and tax expense rose 46.0% to ₹29.50 crore. Against the quarter before, net profit fell 25.4% while total income rose 3.2%.
Revenue from operations rose 14.7% to ₹1,694.65 crore, while other income rose 140.3% to ₹15.45 crore.
Note 6 says that, pursuant to the judgment of the Supreme Court of the United States declaring the reciprocal duties imposed under the International Emergency Economic Powers Act unlawful, the Company has received a refund from U.S. Customs and Border Protection. The note says the Company has recognised an amount of ₹27.97 crore as income and presented it under Other Operating Revenue.
Finance costs fell 8.1% year on year to ₹59.44 crore, but rose 21.6% from ₹48.88 crore in the quarter before. The year-earlier quarter included a tax credit of ₹2.82 crore relating to earlier years. The statement shows an exceptional item, 'Statutory impact of new Labour Codes', of ₹12.45 crore in the year ended 31 Mar 2026 column.
Inference
The statutory auditors' limited review reports that nothing has come to their attention that causes them to believe the statement has not disclosed the required information or contains any material misstatement. The Audit Committee reviewed the results and the Board approved them on 2 Nov 2026.
The company issued 70,000 secured, non-convertible debentures aggregating ₹700 crore on 29 Jan 2024. 30% of the issue, ₹105 crore, was repaid on 29 Jan 2025 and again on 29 Jan 2026, and ₹490 crore is outstanding as at 30 Sep 2026. They are secured by a first-ranking exclusive pledge over certain identified shares of Aquapharm Chemical Limited, a subsidiary, and the security cover is 4.37 times against a requirement of not less than 1.5 times.
Commercial paper of ₹200 crore issued on 23 Apr 2026 was redeemed on 22 Jul 2026, and the company does not have any outstanding commercial paper as at 30 Sep 2026. Total assets were ₹9,183.63 crore at 30 Sep 2026 against ₹8,221.22 crore at 31 Mar 2026. The filing gives no record date for the interim dividend and no reason for the change in inventories of finished goods shown for the quarter.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
